ID: h-822ed52f
Hypothesis
GFAP Perivascular Redistribution (End-Feet Retraction) as True BBB Dysfunction Biomarker
Spatial redistribution of GFAP from astrocyte end-feet to soma — not upregulation — is the mechanistically relevant BBB-dysfunction event, detectable as altered plasma/CSF GFAP ratio and AQP4 depolarization before reactive gliosis onset.
neurodegeneration
EvidencePending (0%)📖 5 cit🗣 1 debates✓ 5 support✗ 2 oppose
✓ All Quality Gates Passed
🧪 Overview
Spatial redistribution of GFAP from astrocyte end-feet to soma — not upregulation — is the mechanistically relevant BBB-dysfunction event, detectable as altered plasma/CSF GFAP ratio and AQP4 depolarization before reactive gliosis onset.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["Astrocyte End-Foot GFAP Network<br/>Perivascular Cytoskeleton"]
B["AQP4 Polarization and Claudin-5 Support<br/>BBB Interface Integrity"]
C["Stress-Driven GFAP Redistribution<br/>End-foot to Soma Shift"]
D["Barrier Support Failure<br/>Neurovascular Coupling Weakens"]
E["Plasma GFAP/S100B Rise<br/>Early BBB Dysfunction Readout"]
F["Pre-symptomatic Neurodegeneration Signal<br/>Astrovascular Injury Window"]
A --> B
C -.->|"disrupts"| B
B --> F
C --> D
D --> E
E --> F
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style D fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style F fill:#1b5e20,stroke:#81c784,color:#81c784⚖️ Evidence
⚖️ Evidence Matrix5 supports2 contradicts
Supports
Hippocampal GFAP-positive astrocyte responses to amyloid and tau pathologies.
Supports
Sequential activation of microglia and astrocyte cytokine expression precedes increased Iba-1 or GFAP immunoreactivity following systemic immune challenge.
Supports
STAT3 Drives GFAP Accumulation and Astrocyte Pathology in a Mouse Model of Alexander Disease.
Supports
Endothelial depletion of Atg7 triggers astrocyte-microvascular disassociation at blood-brain barrier.
Supports
Serum GFAP levels correlate with astrocyte reactivity, post-mortem brain atrophy and neurofibrillary tangles.
Contradicts
Blood GFAP changes occur across Alzheimer biomarker and all-cause dementia contexts, so GFAP alone is not specific for BBB dysfunction or astrocyte end-foot retraction.
Contradicts
Plasma biomarkers associate with both neurodegenerative atrophy and microvascular burden, complicating interpretation of GFAP as a selective neurovascular permeability readout.
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — GFAP
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for GFAP from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for GFAP.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.3%
Volatility
Medium
0.0424
Events (7d)
2
Price History
▼3.2%💾 Resource Usage
LLM Tokens
1,559,664
$5.2824
API Calls
260
Total Cost
$5.2824
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF acute BBB dysfunction is driven by GFAP redistribution from astrocyte end-feet to soma (rather than GFAP upregulation), THEN measuring serial plasma/CSF GFAP ratios in traumatic brain injury patien | CSF GFAP concentration will decrease by ≥30% relative to plasma GFAP within 48 hours, yielding a plasma/CSF ratio >2.0 (vs healthy ratio ~1.0-1.5), with the rat | — no observation — | pending | 0.68 |
| IF AQP4 depolarization co-occurs mechanistically with GFAP end-foot redistribution as a unitary BBB dysfunction event, THEN double-immunostaining for GFAP and AQP4 in postmortem human brain tissue fro | Quantitative microscopy will reveal AQP4 end-foot coverage per vessel decreases from baseline ~85% to <30% with concurrent soma accumulation, detectable in per- | — no observation — | pending | 0.72 |
🔮 Falsifiable Predictions (2)
pendingconf 72%
IF AQP4 depolarization co-occurs mechanistically with GFAP end-foot redistribution as a unitary BBB dysfunction event, THEN double-immunostaining for GFAP and AQP4 in postmortem human brain tissue from ischemic stroke patients who died within 72 hours of onset will show >70% colocalization loss from
Predicted outcome: Quantitative microscopy will reveal AQP4 end-foot coverage per vessel decreases from baseline ~85% to <30% with concurrent soma accumulation, detectab
Falsification: If AQP4 maintains normal perivascular localization (≥70% end-foot coverage) despite confirmed GFAP redistribution events, or if AQP4 depolarization occurs independently without BBB compromise, the mec
pendingconf 68%
IF acute BBB dysfunction is driven by GFAP redistribution from astrocyte end-feet to soma (rather than GFAP upregulation), THEN measuring serial plasma/CSF GFAP ratios in traumatic brain injury patients within 48 hours of injury will reveal decreased CSF GFAP (reflecting end-foot loss) concurrent wi
Predicted outcome: CSF GFAP concentration will decrease by ≥30% relative to plasma GFAP within 48 hours, yielding a plasma/CSF ratio >2.0 (vs healthy ratio ~1.0-1.5), wi
Falsification: If plasma/CSF GFAP ratio remains unchanged (<20% deviation from baseline) despite documented BBB dysfunction (via MRI contrast enhancement or serum S100B), the redistribution hypothesis is falsified.
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.